R&D channel feed

Gavi re­ports 're­bound' year for child­hood vac­ci­na­tions

Last year

FDA ad watch­dog sends first rep­ri­mand of 2023 to Xeris over ‘mis­lead­ing’ drug claims

Last year

Al­ladapt touts da­ta on food al­ler­gy drug as it preps for PhI­II

Last year

Ex­clu­sive: Bat­tle with ‘un­drug­gable’ can­cer tar­get be­ta-catenin heats up, as Sapi­ence dos­es first pa­tient

Last year

Scoop: In­Car­da ter­mi­nates its PhI­II tri­al for ar­rhyth­mia drug that was cen­tral to plans for an IPO

Last year

In­tel­lia’s sec­ond CRISPR ther­a­py re­duces swelling at­tacks by 95% in hered­i­tary an­gioede­ma

Last year

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Last year

FDA wants more da­ta from Abeona Ther­a­peu­tics as it push­es for BLA

Last year
Cell/Gene Tx
Manufacturing

Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

Last year
Financing
Startups

Disc Med­i­cine claims PhII win for re­pur­posed ex-Roche drug in rare blood dis­or­der

Last year

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

Last year

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Last year
Cell/Gene Tx
FDA+

Good clin­i­cal prac­tices: FDA opens up­dat­ed ICH draft guid­ance for com­ments

Last year

Arv­inas’ prostate can­cer treat­ment shows hints of sig­nal — but how many pa­tients will it work for?

Last year

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

Last year
Cell/Gene Tx

Ak­ili re­leas­es non-pre­scrip­tion ver­sion of video game dig­i­tal ther­a­py for adults with AD­HD

Last year

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Last year
Deals
Cell/Gene Tx

Fi­bro­Gen grap­ples with PhI­II set­back in Duchenne mus­cu­lar dy­s­tro­phy

Last year

Day One goes to the mar­ket for $150M as biotech kicks off NDA re­quest for pe­di­atric brain can­cer drug

Last year
Financing

Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

Last year

Ear­ly da­ta show Bicara’s bis­pe­cif­ic helps shrink head and neck can­cers when com­bined with Keytru­da: #AS­CO23

Last year

Bio­gen cuts PhI­II Parkin­son’s pro­gram over ‘long time­line’ 

Last year

Bellerophon's stock tanks as in­haled drug-de­vice fails to re­deem it­self in new PhI­II af­ter pre­vi­ous flops

Last year

Akero’s NASH can­di­date re­duces liv­er fat in pa­tients tak­ing a GLP-1

Last year
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times